Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings

被引:11
作者
Kendi, Caroline [1 ]
Penner, Jeremy [1 ,2 ]
Koech, Julius [1 ]
Nyonda, Mary [1 ]
Cohen, Craig R. [3 ]
Bukusi, Elizabeth A. [1 ]
Ngugi, Evelyn [4 ]
Meyer, Ana-Claire Lew [1 ,5 ]
机构
[1] Kenya Govt Med Res Ctr, Ctr Microbiol Res, Family AIDS Care & Educ Serv, Nairobi, Kenya
[2] Univ British Columbia, Dept Family Practice, Vancouver, BC V5Z 1M9, Canada
[3] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA
[4] Ctr Dis Control & Prevent, Div Global HIV AIDS Care & Treatment USA, Nairobi, Kenya
[5] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurol, San Francisco, CA USA
基金
美国国家卫生研究院;
关键词
HIGH-DOSE FLUCONAZOLE; AIDS PATIENTS; ANTIRETROVIRAL THERAPY; NATURAL-HISTORY; EARLY MORTALITY; AMPHOTERICIN-B; INFECTION; COHORT; SURVEILLANCE; FLUCYTOSINE;
D O I
10.1136/postgradmedj-2012-130823
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose Cryptococcal meningitis is a leading cause of mortality among HIV-infected individuals in sub-Saharan Africa but little is known about its treatment and outcomes in decentralised HIV outpatient settings. We assessed adherence to treatment guidelines and determined predictors of survival. Design A computerised laboratory database identified HIV-infected adults with cryptococcal meningitis at Family AIDS Care and Education Services in Nyanza Province, Kenya, between 2005-2009. Medical records were reviewed. Kaplan-Meier survival curves were generated. Bivariate and multivariate Cox proportional hazards models were used to determine associations between key clinical characteristics and survival. Results Medical records were located for 79% (71/90). Mortality was 38% (27/71) over a median follow-up period of 201 days (IQR: 10-705 days). Adherence to local guidelines for treatment of cryptococcal meningitis was 48% (34/71). Higher body mass index was associated with improved survival (HR: 0.82, 95% CI (0.68 to 0.99)) even after controlling for factors such as age, CD4 cell count, receipt of highly active antiretroviral therapy, and treatment with any anti-fungal therapy. Conclusions Cryptococcal meningitis diagnosed in routine HIV outpatient settings is largely treated as an outpatient and adherence to treatment guidelines is poor. Body mass index is a critical independent predictor of outcome. Additional research to determine the most effective strategies to reduce premature mortality is urgently needed.
引用
收藏
页码:73 / 77
页数:5
相关论文
共 29 条
[1]   The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis [J].
Antinori, S ;
Radice, A ;
Galimberti, L ;
Magni, C ;
Fasan, M ;
Parravicini, C .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (11) :5828-5829
[2]   Cryptococcus neoformans infection in a cohort of Italian AIDS patients:: Natural history, early prognostic parameters, and autopsy findings [J].
Antinori, S ;
Galimberti, L ;
Magni, C ;
Casella, A ;
Vago, L ;
Mainini, F ;
Piazza, M ;
Nebuloni, M ;
Fasan, M ;
Bonaccorso, C ;
Vigevani, GM ;
Cargnel, A ;
Moroni, M ;
Ridolfo, A .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (10) :711-717
[3]   Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole [J].
Bicanic, Tihana ;
Meintjes, Graeme ;
Wood, Robin ;
Hayes, Madeleine ;
Rebe, Kevin ;
Bekker, Linda-Gail ;
Harrison, Thomas .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (01) :76-80
[4]   Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients [J].
Bicanic, Tihana ;
Muzoora, Conrad ;
Brouwer, Annemarie E. ;
Meintjes, Graeme ;
Longley, Nicky ;
Taseera, Kabanda ;
Rebe, Kevin ;
Loyse, Angela ;
Jarvis, Joseph ;
Bekker, Linda-Gail ;
Wood, Robin ;
Limmathurotsakul, Direk ;
Chierakul, Wirongrong ;
Stepniewska, Kasia ;
White, Nicholas J. ;
Jaffar, Shabbar ;
Harrison, Thomas S. .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (05) :702-709
[5]   INFECTIONS WITH CRYPTOCOCCUS-NEOFORMANS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
CHUCK, SL ;
SANDE, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (12) :794-799
[6]   THE VALUE OF CRYPTOCOCCAL SERUM ANTIGEN SCREENING AMONG HIV-POSITIVE AIDS PATIENTS IN KINSHASA, ZAIRE [J].
DESMET, P ;
KAYEMBE, KD ;
DEVROEY, C .
AIDS, 1989, 3 (02) :77-78
[7]   Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults [J].
French, N ;
Gray, K ;
Watera, C ;
Nakiyingi, J ;
Lugada, E ;
Moore, M ;
Lalloo, D ;
Whitworth, JAG ;
Gilks, CF .
AIDS, 2002, 16 (07) :1031-1038
[8]   Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa [J].
Jarvis, Joseph N. ;
Lawn, Stephen D. ;
Vogt, Monica ;
Bangani, Nonzwakazi ;
Wood, Robin ;
Harrison, Thomas S. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (07) :856-862
[9]   Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection [J].
Jongwutiwes, Ubonvan ;
Kiertiburanakul, Sasisopin ;
Sungkanuparph, Somnuek .
CURRENT HIV RESEARCH, 2007, 5 (03) :355-360
[10]   Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy [J].
Kambugu, Andrew ;
Meya, David B. ;
Rhein, Joshua ;
O'Brien, Meagan ;
Janoff, Edward N. ;
Ronald, Allan R. ;
Kamya, Moses R. ;
Mayanja-Kizza, Harriet ;
Sande, Merle A. ;
Bohjanen, Paul R. ;
Boulware, David R. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (11) :1694-1701